Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

Clinical trial NCT05906953 · RECRUITING

Trial details

NCT number: NCT05906953
Sponsor: HuidaGene Therapeutics Co., Ltd.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leber Congenital Amaurosis Inherited Retinal Diseases Caused by RPE65 Mutations

Start date: 2023-10-31
Primary completion: 2025-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.